Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients.
about
Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinomaStrategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantationTumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCCTreatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expressionDickkopfs and Wnt/β-catenin signalling in liver cancerAsian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors.Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver diseaseAlpha-1-acid glycoprotein as potential biomarker for alpha-fetoprotein-low hepatocellular carcinomaProtein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation.Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma.Measurement of glycosylated alpha-fetoprotein improves diagnostic power over the native form in hepatocellular carcinomaFrequency of and predictive factors for vascular invasion after radiofrequency ablation for hepatocellular carcinoma.Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation.The value of serum midkine level in diagnosis of hepatocellular carcinoma.Clinical utility of protein induced by vitamin K absence in patients with chronic hepatitis B virus infectionUtility of serum des-gamma-carboxyprothrombin in the diagnosis of hepatocellular carcinoma among Nigerians, a case-control studyDNA markers in molecular diagnostics for hepatocellular carcinoma.Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again.Percutaneous transsplenic embolization of esophageal and gastrio-fundal varices in 18 patientsPrediction of vascular invasion in hepatocellular carcinoma by next-generation des-r-carboxy prothrombinRadiation therapy for portal venous invasion by hepatocellular carcinoma.Emergency endoscopic variceal ligation following variceal rupture in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis: a retrospective study.Surveillance and Diagnosis of Hepatocellular Carcinoma.Epidemiology and surveillance of hepatocellular carcinoma.Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma.Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients.Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis.Preoperative prognostic values of α-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) in patients with hepatocellular carcinoma for living donor liver transplantation.Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review.Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinomaHepatocellular carcinoma: diagnostics and screening.Cancer biomarkers for hepatocellular carcinomas: from traditional markers to recent topics.Efficacy of surgical microwave therapy in patients with unresectable hepatocellular carcinoma.Markers for microvascular invasion in hepatocellular carcinoma: where do we stand?Predictors for microinvasion of small hepatocellular carcinoma ≤ 2 cm.Adjuvant therapy after curative treatment for hepatocellular carcinoma.Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this?Outcomes and predictors of microvascular invasion of solitary hepatocellular carcinoma.
P2860
Q24635267-3538B5A0-5F47-49CE-9164-081B977C3127Q27005375-09EE4D9A-B2B8-4D2F-83CC-F4ECA15EC0A6Q27011253-4D316D90-236C-49DC-A40D-6D8C7050C953Q27485914-D36C52D2-50F7-4D7A-AC58-EB20AC81E8A3Q28391394-6EB2733E-2842-4AFF-B8AA-86E0D3BD3BE1Q30479629-D78179AE-87F0-4F3B-8854-6933B86816ECQ30512830-AAB7C6FE-51D6-42D1-8B8C-B40EAF1C1474Q33344056-D7333075-797E-4F66-A11B-B31B108D044EQ33353052-271D9A6E-57A9-4D41-BBCF-A92272065BB3Q33752079-CE4AA262-0413-46E6-ACE7-32A05B15BB01Q34045477-3DF218D5-F5BC-4129-A5FC-00184D6ABB94Q34201437-42282A64-1845-4B45-B7A2-5AD012435286Q34332296-4D988097-3B4B-4992-9EB6-6A102BB78B56Q34513574-76342316-801E-4B15-82BE-B0874DF8303DQ34660116-25046EA5-F7F7-4075-B4F0-91C2F486C1A9Q35110135-252E15A8-A5A1-4CB7-81D9-FAE20732299DQ35125611-52690548-650F-4255-9378-80D6C6B04D78Q35764990-6B134BFC-E896-4F0E-A896-5F14EBBF3041Q35781255-2098F986-9AEA-4D4F-A4EF-4D96468C9A45Q36082480-DF896E1B-7DB3-4102-BFC2-EF7305188122Q36415749-54D7302D-A5D0-473A-B105-80C41C8831A1Q36472993-340B9CA2-98E9-468F-9FD4-6473E80C85A2Q36497043-F9EA17EF-2F2A-4B34-81FC-700502D8B162Q36612038-289E88D1-16D2-4028-8D77-DD7C11A53E38Q36812480-2E328ACF-8FED-4D8B-BAB0-67EE6EAA07E7Q37105532-A68110AA-9E5A-4BFF-9B4A-30C907EC1229Q37220662-B1103776-EC16-4770-9993-D196B9E0FFF9Q37350320-E9EE6D84-5A6F-4CF0-83BB-03999E380AAEQ37534070-CC9B74B3-24D4-4C8C-8F7E-71918C1C29D5Q37568646-4025733F-53F5-4765-BEFE-4DA19730D13CQ37577551-76378F28-ACA2-4AC1-A3C0-341B0519851BQ37725272-CB442995-AD2A-4E67-9EF9-881839FF272BQ37813192-589287F1-18E9-44E0-B387-9EA9AA41138BQ37856310-B0936ED2-460D-47DB-AA48-2AEB6D3EFC51Q37889718-7531DEF6-D159-4D81-AADC-D3E40B335194Q37895618-60AB9F4A-8BED-4097-93AD-45A7B7A9E153Q37971850-125B19FD-DA4B-48B4-B8F0-8EE8BB56A66FQ37972807-909B2560-8356-4D5A-807D-8F7E4DFD86E3Q38065315-B7BE2AD9-26C9-4BD6-B0EF-5515BD661F9AQ38120031-AF982712-8218-421C-95AF-D84E248E7F08
P2860
Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Des-gamma-carboxy prothrombin ...... tive analysis of 227 patients.
@ast
Des-gamma-carboxy prothrombin ...... tive analysis of 227 patients.
@en
type
label
Des-gamma-carboxy prothrombin ...... tive analysis of 227 patients.
@ast
Des-gamma-carboxy prothrombin ...... tive analysis of 227 patients.
@en
prefLabel
Des-gamma-carboxy prothrombin ...... tive analysis of 227 patients.
@ast
Des-gamma-carboxy prothrombin ...... tive analysis of 227 patients.
@en
P2093
P2860
P1433
P1476
Des-gamma-carboxy prothrombin ...... tive analysis of 227 patients.
@en
P2093
Shiratori Y
Teratani T
P2860
P304
P356
10.1002/1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO;2-N
P407
P577
2001-02-01T00:00:00Z